<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Headache: A Comprehensive Guide</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&family=Outfit:wght@700&display=swap" rel="stylesheet">
    <style>
        body {
            font-family: 'Inter', sans-serif;
            background-color: #121212; /* Dark background */
            color: #e0e0e0; /* Light grey for text */
        }
        h1, h2, h3, h4, h5, h6 {
            font-family: 'Outfit', sans-serif;
            color: #ffffff; /* White for headings */
        }
        .gradient-text {
            background: linear-gradient(90deg, #a855f7, #ec4899, #f43f5e);
            -webkit-background-clip: text;
            background-clip: text;
            color: transparent;
        }
        .card {
            background: rgba(255, 255, 255, 0.05); /* Subtle glassmorphism */
            backdrop-filter: blur(10px);
            -webkit-backdrop-filter: blur(10px);
            border: 1px solid rgba(255, 255, 255, 0.1);
            border-radius: 12px;
            box-shadow: 0 8px 32px 0 rgba(0, 0, 0, 0.3);
            transition: transform 0.3s ease, box-shadow 0.3s ease;
        }
        .card:hover {
            transform: translateY(-5px);
            box-shadow: 0 12px 40px 0 rgba(0, 0, 0, 0.4);
        }
        .card-header {
            background: rgba(255, 255, 255, 0.1);
            backdrop-filter: blur(5px);
            -webkit-backdrop-filter: blur(5px);
            border-bottom: 1px solid rgba(255, 255, 255, 0.1);
            border-top-left-radius: 12px;
            border-top-right-radius: 12px;
        }
        .accordion-header {
            cursor: pointer;
            transition: background-color 0.3s ease;
        }
        .accordion-header:hover {
            background-color: rgba(255, 255, 255, 0.15);
        }
        .accordion-content {
            max-height: 0;
            overflow: hidden;
            transition: max-height 0.3s ease-out, padding 0.3s ease-out;
        }
        .accordion-content.open {
            max-height: 500px; /* Adjust as needed */
            padding-top: 1rem;
            padding-bottom: 1rem;
        }
        .list-item {
            position: relative;
            padding-left: 20px;
            margin-bottom: 8px;
        }
        .list-item::before {
            content: '';
            position: absolute;
            left: 0;
            top: 8px;
            width: 8px;
            height: 8px;
            background-color: #f472b6; /* Pink accent */
            border-radius: 50%;
            transition: transform 0.3s ease;
        }
        .list-item:hover::before {
            transform: scale(1.2);
        }
        .red-flag::before {
            background-color: #ef4444; /* Red accent for red flags */
        }
        .subtle-shadow {
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
        }
        /* Custom Scrollbar */
        ::-webkit-scrollbar {
            width: 8px;
        }
        ::-webkit-scrollbar-track {
            background: #1e1e1e;
            border-radius: 4px;
        }
        ::-webkit-scrollbar-thumb {
            background: #6b21a8; /* Purple accent */
            border-radius: 4px;
        }
        ::-webkit-scrollbar-thumb:hover {
            background: #8b5cf6;
        }
    </style>
    <script>
        // Tailwind CSS Configuration Extension (if needed)
        tailwind.config = {
            theme: {
                extend: {
                    fontFamily: {
                        sans: ['Inter', 'sans-serif'],
                        display: ['Outfit', 'sans-serif'],
                    },
                    colors: {
                        primary: '#8b5cf6', // Purple
                        secondary: '#f472b6', // Pink
                        accent: '#22d3ee', // Cyan
                        dark: {
                            bg: '#121212',
                            card: 'rgba(255, 255, 255, 0.05)',
                            border: 'rgba(255, 255, 255, 0.1)',
                            text: '#e0e0e0',
                            heading: '#ffffff',
                            'card-header': 'rgba(255, 255, 255, 0.1)'
                        },
                        light: {
                            text: '#333333'
                        }
                    },
                    boxShadow: {
                        'glass': '0 8px 32px 0 rgba(0, 0, 0, 0.3)',
                        'card-hover': '0 12px 40px 0 rgba(0, 0, 0, 0.4)'
                    }
                }
            }
        };
    </script>
</head>
<body class="antialiased">

    <header class="py-16 md:py-24 px-6 md:px-12 text-center relative overflow-hidden">
        <div class="absolute inset-0 -z-10 overflow-hidden">
            <div class="absolute top-0 left-0 w-full h-full bg-gradient-to-br from-purple-700 via-pink-500 to-red-500 opacity-30 filter blur-xl md:blur-2xl animate-pulse"></div>
            <div class="absolute bottom-0 right-0 w-full h-full bg-gradient-to-tl from-blue-500 via-cyan-400 to-teal-400 opacity-20 filter blur-xl md:blur-2xl animate-pulse animation-delay-2000"></div>
        </div>
        <h1 class="text-4xl md:text-6xl font-bold mb-4 leading-tight">Headache: A Comprehensive Guide</h1>
        <p class="text-lg md:text-2xl text-gray-300 max-w-3xl mx-auto">Understanding Types, Pathophysiology, Diagnosis, and Management of Headaches.</p>
    </header>

    <main class="container mx-auto px-6 md:px-12 py-12 md:py-20">

        <section id="definition-epidemiology" class="card p-8 mb-12">
            <div class="card-header p-4 mb-6">
                <h2 class="text-3xl font-bold">Definition and Epidemiology</h2>
            </div>
            <p class="mb-6 text-lg leading-relaxed">Headache is defined as pain in any region of the head and is a very common neurological symptom. Headaches are categorized into primary (not caused by an underlying condition) and secondary (symptoms of another disorder) types, with diagnostic criteria provided by the International Classification of Headache Disorders, 3rd edition (ICHD-3).</p>
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6">
                <div class="text-center">
                    <p class="text-3xl font-bold text-accent">90-95%</p>
                    <p class="text-gray-300">Lifetime Prevalence</p>
                </div>
                <div class="text-center">
                    <p class="text-3xl font-bold text-secondary">12-15%</p>
                    <p class="text-gray-300">Migraine Prevalence</p>
                </div>
                <div class="text-center">
                    <p class="text-3xl font-bold text-primary">~70%</p>
                    <p class="text-gray-300">Tension-Type Headache Prevalence</p>
                </div>
            </div>
        </section>

        <section id="pathophysiology" class="card p-8 mb-12">
            <div class="card-header p-4 mb-6">
                <h2 class="text-3xl font-bold">Pathophysiology</h2>
            </div>
            <div class="grid grid-cols-1 lg:grid-cols-3 gap-8">
                <div class="flex flex-col">
                    <h3 class="text-2xl font-semibold mb-4 text-accent">Migraine</h3>
                    <ul class="list-disc list-inside text-gray-300 space-y-2">
                        <li>Altered neuronal excitability</li>
                        <li>Trigeminal nervous system activation</li>
                        <li>Cortical Spreading Depression (CSD)</li>
                        <li>Neurogenic inflammation</li>
                        <li>Central sensitization</li>
                    </ul>
                </div>
                <div class="flex flex-col">
                    <h3 class="text-2xl font-semibold mb-4 text-secondary">Tension-Type Headache (TTH)</h3>
                    <ul class="list-disc list-inside text-gray-300 space-y-2">
                        <li>Peripheral mechanisms (episodic)</li>
                        <li>Central sensitization (chronic)</li>
                        <li>Dysregulation of descending pain pathways</li>
                    </ul>
                </div>
                <div class="flex flex-col">
                    <h3 class="text-2xl font-semibold mb-4 text-primary">Cluster Headache</h3>
                    <ul class="list-disc list-inside text-gray-300 space-y-2">
                        <li>Hypothalamic dysfunction</li>
                        <li>Trigeminal autonomic reflex</li>
                        <li>CGRP involvement</li>
                        <li>Autonomic symptoms</li>
                    </ul>
                </div>
            </div>
        </section>

        <section id="clinical-presentation" class="card p-8 mb-12">
            <div class="card-header p-4 mb-6">
                <h2 class="text-3xl font-bold">Clinical Presentation</h2>
            </div>
            <div class="grid grid-cols-1 lg:grid-cols-3 gap-8">
                <div class="flex flex-col">
                    <h3 class="text-2xl font-semibold mb-4 text-accent">Migraine</h3>
                    <ul class="list-item-bullet text-gray-300 space-y-2">
                        <li>4-72 hours duration</li>
                        <li>Unilateral, pulsating, moderate-to-severe</li>
                        <li>Aggravated by activity</li>
                        <li>Nausea/vomiting, photophobia/phonophobia</li>
                        <li>May have aura</li>
                    </ul>
                </div>
                <div class="flex flex-col">
                    <h3 class="text-2xl font-semibold mb-4 text-secondary">Tension-Type Headache (TTH)</h3>
                    <ul class="list-item-bullet text-gray-300 space-y-2">
                        <li>30 mins to 7 days duration</li>
                        <li>Bilateral, pressing/tightening, mild-to-moderate</li>
                        <li>Not aggravated by activity</li>
                        <li>No nausea/vomiting; +/- photophobia or phonophobia</li>
                    </ul>
                </div>
                <div class="flex flex-col">
                    <h3 class="text-2xl font-semibold mb-4 text-primary">Cluster Headache</h3>
                    <ul class="list-item-bullet text-gray-300 space-y-2">
                        <li>15-180 mins per attack, in bouts</li>
                        <li>Severe unilateral orbital/supraorbital/temporal pain</li>
                        <li>Ipsilateral autonomic symptoms (lacrimation, rhinorrhea, etc.)</li>
                        <li>Restlessness/agitation</li>
                    </ul>
                </div>
            </div>
            <p class="text-sm text-gray-400 mt-6 italic">All criteria based on ICHD-3.</p>
        </section>

        <section id="diagnostic-criteria" class="card p-8 mb-12">
            <div class="card-header p-4 mb-6">
                <h2 class="text-3xl font-bold">Diagnostic Criteria & Red Flags</h2>
            </div>
            <p class="mb-6 text-lg leading-relaxed">Diagnosis of primary headaches relies on detailed history and neurological examination, following ICHD-3 criteria. A normal exam is crucial to rule out secondary causes. The SNOOP10 mnemonic highlights red flags for secondary headaches requiring investigation:</p>
            <div class="grid grid-cols-1 lg:grid-cols-2 gap-8">
                <div>
                    <h3 class="text-2xl font-semibold mb-4 text-accent">Key Diagnostic Steps</h3>
                    <ul class="list-item text-gray-300 space-y-2">
                        <li>Detailed History (Onset, Duration, Frequency, Quality, Intensity, Location, Triggers, etc.)</li>
                        <li>Neurological Examination</li>
                    </ul>
                </div>
                <div>
                    <h3 class="text-2xl font-semibold mb-4 text-red-500">Red Flags (SNOOP10)</h3>
                    <ul class="list-item red-flag text-gray-300 space-y-2">
                        <li><strong>S</strong>ystemic symptoms (fever, weight loss, cancer)</li>
                        <li><strong>N</strong>eurologic symptoms/abnormal signs (altered mental status, focal deficits)</li>
                        <li><strong>O</strong>nset: New onset or change in pattern (sudden/thunderclap, >50 yrs)</li>
                        <li><strong>O</strong>ther associated conditions (trauma, drug use, pregnancy)</li>
                        <li><strong>P</strong>rogressive headache pattern</li>
                        <li><strong>P</strong>apilledema</li>
                        <li><strong>P</strong>ostural aggravation</li>
                        <li><strong>P</strong>recipitated by Valsalva/Exertion</li>
                        <li><strong>P</strong>regnancy</li>
                    </ul>
                </div>
            </div>
        </section>

        <section id="management" class="mb-12">
            <div class="card p-8 mb-8">
                <div class="card-header p-4 mb-6">
                    <h2 class="text-3xl font-bold">Management Overview</h2>
                </div>
                <p class="text-lg leading-relaxed">Management strategies vary by headache type, including acute (abortive) and preventive therapies. Accurate diagnosis is key to effective treatment.</p>
            </div>

            <div class="grid grid-cols-1 gap-8">
                <div>
                    <h3 class="text-3xl font-bold text-center mb-6 text-accent">Migraine Management</h3>
                    <div class="space-y-4">
                        <div class="card p-6">
                            <div class="accordion-header p-3 flex justify-between items-center" onclick="toggleAccordion(this)">
                                <h4 class="text-xl font-semibold">Acute Treatment</h4>
                                <svg class="w-6 h-6 transform transition-transform duration-300" fill="none" stroke="currentColor" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7"></path></svg>
                            </div>
                            <div class="accordion-content p-4">
                                <p class="mb-4 text-gray-300">Aims for rapid and consistent attack treatment.</p>
                                <div class="grid grid-cols-1 md:grid-cols-2 gap-4">
                                    <div>
                                        <h5 class="font-bold text-lg mb-2">Mild-to-Moderate Attacks:</h5>
                                        <ul class="list-item text-gray-300 text-sm space-y-1">
                                            <li>NSAIDs (Ibuprofen, Naproxen)</li>
                                            <li>Acetaminophen</li>
                                            <li>Combination Analgesics (Acetaminophen/Aspirin/Caffeine)</li>
                                        </ul>
                                    </div>
                                    <div>
                                        <h5 class="font-bold text-lg mb-2">Moderate-to-Severe Attacks:</h5>
                                        <ul class="list-item text-gray-300 text-sm space-y-1">
                                            <li>Triptans (Sumatriptan, Rizatriptan)</li>
                                            <li>CGRP Receptor Antagonists (Gepants: Rimegepant, Ubrogepant)</li>
                                            <li>Ditans (Lasmiditan)</li>
                                            <li>Antiemetics (Metoclopramide)</li>
                                        </ul>
                                    </div>
                                </div>
                                <p class="text-xs text-gray-400 mt-3 italic">Note: Specific dosages and contraindications apply.</p>
                            </div>
                        </div>
                        <div class="card p-6">
                            <div class="accordion-header p-3 flex justify-between items-center" onclick="toggleAccordion(this)">
                                <h4 class="text-xl font-semibold">Preventive Treatment</h4>
                                <svg class="w-6 h-6 transform transition-transform duration-300" fill="none" stroke="currentColor" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7"></path></svg>
                            </div>
                            <div class="accordion-content p-4">
                                <p class="mb-4 text-gray-300">Considered for frequent headaches or significant disability.</p>
                                <div class="grid grid-cols-1 md:grid-cols-2 gap-4">
                                    <div>
                                        <h5 class="font-bold text-lg mb-2">Oral Agents:</h5>
                                        <ul class="list-item text-gray-300 text-sm space-y-1">
                                            <li>Beta-blockers (Propranolol)</li>
                                            <li>Anticonvulsants (Topiramate)</li>
                                            <li>Antidepressants (Amitriptyline)</li>
                                        </ul>
                                    </div>
                                    <div>
                                        <h5 class="font-bold text-lg mb-2">Other Therapies:</h5>
                                        <ul class="list-item text-gray-300 text-sm space-y-1">
                                            <li>CGRP Monoclonal Antibodies (mAbs)</li>
                                            <li>OnabotulinumtoxinA (Botox for chronic migraine)</li>
                                            <li>Neuromodulation Devices</li>
                                        </ul>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>

                <div>
                    <h3 class="text-3xl font-bold text-center mb-6 text-secondary">Tension-Type Headache (TTH) Management</h3>
                    <div class="space-y-4">
                        <div class="card p-6">
                            <div class="accordion-header p-3 flex justify-between items-center" onclick="toggleAccordion(this)">
                                <h4 class="text-xl font-semibold">Acute Treatment</h4>
                                <svg class="w-6 h-6 transform transition-transform duration-300" fill="none" stroke="currentColor" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7"></path></svg>
                            </div>
                            <div class="accordion-content p-4">
                                <ul class="list-item text-gray-300 text-sm space-y-1">
                                    <li>Simple Analgesics (Aspirin, Ibuprofen, Acetaminophen)</li>
                                    <li>Combination Analgesics</li>
                                </ul>
                                <p class="text-xs text-gray-400 mt-3 italic">Use sparingly to avoid medication overuse headache.</p>
                            </div>
                        </div>
                        <div class="card p-6">
                            <div class="accordion-header p-3 flex justify-between items-center" onclick="toggleAccordion(this)">
                                <h4 class="text-xl font-semibold">Preventive Treatment</h4>
                                <svg class="w-6 h-6 transform transition-transform duration-300" fill="none" stroke="currentColor" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7"></path></svg>
                            </div>
                            <div class="accordion-content p-4">
                                <ul class="list-item text-gray-300 text-sm space-y-1">
                                    <li>Tricyclic Antidepressants (TCAs: Amitriptyline)</li>
                                    <li>Non-pharmacological approaches (Biofeedback, CBT)</li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>

                <div>
                    <h3 class="text-3xl font-bold text-center mb-6 text-primary">Cluster Headache Management</h3>
                    <div class="space-y-4">
                        <div class="card p-6">
                            <div class="accordion-header p-3 flex justify-between items-center" onclick="toggleAccordion(this)">
                                <h4 class="text-xl font-semibold">Acute Treatment</h4>
                                <svg class="w-6 h-6 transform transition-transform duration-300" fill="none" stroke="currentColor" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7"></path></svg>
                            </div>
                            <div class="accordion-content p-4">
                                <ul class="list-item text-gray-300 text-sm space-y-1">
                                    <li>100% Oxygen (high flow)</li>
                                    <li>Triptans (Sumatriptan SC injection, Zolmitriptan nasal spray)</li>
                                </ul>
                                <p class="text-xs text-gray-400 mt-3 italic">Oral triptans are generally too slow.</p>
                            </div>
                        </div>
                        <div class="card p-6">
                            <div class="accordion-header p-3 flex justify-between items-center" onclick="toggleAccordion(this)">
                                <h4 class="text-xl font-semibold">Preventive Treatment</h4>
                                <svg class="w-6 h-6 transform transition-transform duration-300" fill="none" stroke="currentColor" viewBox="0 0 24 24" xmlns="http://www.w3.org/2000/svg"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7"></path></svg>
                            </div>
                            <div class="accordion-content p-4">
                                <ul class="list-item text-gray-300 text-sm space-y-1">
                                    <li>First-line: Verapamil</li>
                                    <li>Second-line/Add-on: Lithium, Topiramate</li>
                                    <li>Galcanezumab (episodic cluster headache)</li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </section>

        <section id="special-populations" class="card p-8 mb-12">
            <div class="card-header p-4 mb-6">
                <h2 class="text-3xl font-bold">Special Populations</h2>
            </div>
            <div class="grid grid-cols-1 lg:grid-cols-2 gap-8">
                <div>
                    <h3 class="text-2xl font-semibold mb-4 text-accent">Pregnancy and Lactation</h3>
                    <ul class="list-item text-gray-300 space-y-2">
                        <li><strong>Acute Migraine:</strong> Acetaminophen first-line. NSAIDs (first two trimesters). Triptans (low-risk if needed).</li>
                        <li><strong>Preventive Migraine:</strong> Beta-blockers, Amitriptyline preferred. Valproate/Topiramate generally contraindicated.</li>
                    </ul>
                </div>
                <div>
                    <h3 class="text-2xl font-semibold mb-4 text-secondary">Children and Adolescents</h3>
                    <ul class="list-item text-gray-300 space-y-2">
                        <li><strong>Acute Migraine:</strong> Ibuprofen, Acetaminophen first-line. Triptans approved for adolescents.</li>
                        <li><strong>Preventive Migraine:</strong> Non-pharmacological emphasized. Topiramate/Propranolol for refractory cases.</li>
                    </ul>
                </div>
            </div>
        </section>

        <section id="controversies-updates" class="card p-8 mb-12">
            <div class="card-header p-4 mb-6">
                <h2 class="text-3xl font-bold">Controversies & Recent Updates</h2>
            </div>
            <div class="grid grid-cols-1 lg:grid-cols-2 gap-8">
                <div>
                    <h3 class="text-2xl font-semibold mb-4 text-primary">Recent Updates</h3>
                    <ul class="list-item text-gray-300 space-y-2">
                        <li><strong>CGRP Pathway Therapies:</strong> mAbs (Erenumab, Fremanezumab, etc.) and oral gepants (Rimegepant, Ubrogepant) revolutionizing migraine prevention and acute treatment.</li>
                        <li><strong>Ditans (Lasmiditan):</strong> Non-vasoconstrictive acute treatment option.</li>
                        <li><strong>Neuromodulation Devices:</strong> Growing evidence for nVNS, sTMS.</li>
                    </ul>
                </div>
                <div>
                    <h3 class="text-2xl font-semibold mb-4 text-red-500">Controversies</h3>
                    <ul class="list-item text-gray-300 space-y-2">
                        <li><strong>Medication Overuse Headache (MOH):</strong> Frequent acute medication use can worsen headaches; withdrawal strategies debated.</li>
                        <li><strong>Refractory Migraine:</strong> Optimizing sequencing of newer therapies for non-responders.</li>
                        <li><strong>Subtype Classification:</strong> Continued research into biomarkers for individualized treatment.</li>
                    </ul>
                </div>
            </div>
        </section>

        <section id="references" class="card p-8 mb-12">
            <div class="card-header p-4 mb-6">
                <h2 class="text-3xl font-bold">References</h2>
            </div>
            <ul class="list-decimal list-inside text-gray-400 text-sm space-y-2">
                <li>Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). *Cephalalgia*. 2013;33(9):629-808.</li>
                <li>Stovner LJ, Hagen K, Jensen R, et al. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. *J Headache Pain*. 2022;23(1):34.</li>
                <li>Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. *Neurology*. 2007;68(5):343-349.</li>
                <li>Victor TW, Hu X, Campbell JC, et al. Migraine prevalence in the United States: data from the American Migraine Prevalence and Prevention Study. *Headache*. 2010;50(1):1061-1064.</li>
                <li>Bendtsen L. Tension-type headache: an update on pathophysiology, diagnosis, and treatment. *Curr Pain Headache Rep*. 2020;24(1):2.</li>
                <li>May A, Schwedt TJ. Cluster Headache. *Neurology*. 2023;100(17):793-802.</li>
                <li>Charles A. Migraine. *N Engl J Med*. 2017;377(6):553-561.</li>
                <li>Goadsby PJ. An update of the pathophysiology of migraine. *Neuralgia*. 2007;12(Suppl 1):S7-S10.</li>
                <li>Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. *J Neurosci*. 2015;35(17):6619-6629.</li>
                <li>Denuelle M, Fabre N, Payoux P, et al. Hypothalamic activation in spontaneous migraine attacks. *Headache*. 2007;47(10):1418-1424.</li>
                <li>Jensen R, Stovner LJ. Tension-type headache: review of epidemiology, etiology, and management. *Curr Pain Headache Rep*. 2008;12(6):462-469.</li>
                <li>Shahlaie K, Kliot M. Tension-type headache. In: *Handbook of Clinical Neurology*. Vol 165. Elsevier; 2019:205-212.</li>
                <li>May A, Leone M, Afra J, et al. EFNS guidelines on the treatment of cluster headache and other trigeminal autonomic cephalalgias. *Eur J Neurol*. 2006;13(10):1034-1047.</li>
                <li>Goadsby PJ, Cohen AS. Pathophysiology of Cluster Headache: A Trigeminal Autonomic Cephalalgia. *Handb Clin Neurol*. 2010;97:1-13.</li>
                <li>Edvinsson L. The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine and Cluster Headache. *Curr Pain Headache Rep*. 2013;17(12):373.</li>
                <li>Dodick DW. Clinical practice. Acute treatment of migraine. *N Engl J Med*. 2010;362(15):1402-1409.</li>
                <li>American Headache Society. The American Headache Society Position Statement on Integrating New Migraine Treatments into Clinical Practice. *Headache*. 2019;59(1):1-18.</li>
                <li>Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for acute migraine treatment: an evidence-based review. *Headache*. 2012;52(Suppl 2):1-78.</li>
                <li>Goadsby PJ, Dodick DW, Ailani J, et al. Safety, Tolerability, and Efficacy of Ubrogepant for the Acute Treatment of Migraine: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study. *JAMA Neurol*. 2019;76(4):421-428.</li>
                <li>Croop R, Goadsby PJ, Ayata C, et al. Efficacy and Safety of Rimegepant Oral Dissolving Tablet for the Acute Treatment of Migraine: A Phase 3, Randomized, Controlled Trial. *Lancet*. 2019;394(10200):737-745.</li>
                <li>Goadsby PJ, Wietecha LA, Dettmer P, et al. Lasmiditan for the acute treatment of migraine: a phase 3, randomised, controlled, multicentre trial (SAMURAI). *Lancet Neurol*. 2019;18(4):346-357.</li>
                <li>Silberstein SD. Practice parameter: evidence-based guidelines for migraine prophylactic treatment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology*. 2000;55(6):754-762.</li>
                <li>Goadsby PJ, Reuter U, Hallström Y, et al. A Controlled Trial of Erenumab for Episodic Migraine. *N Engl J Med*. 2017;377(22):2123-2132.</li>
                <li>Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. *JAMA Neurol*. 2018;75(9):1080-1088.</li>
                <li>Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the PREEMPT 2 randomized controlled trial. *Cephalalgia*. 2010;30(7):793-803.</li>
                <li>Bendtsen L, Evers S, Linde M, et al. EFNS guideline on the treatment of tension-type headache—report of an EFNS task force. *Eur J Neurol*. 2010;17(10):1249-1255.</li>
                <li>Goadsby PJ, Gawel MJ, Fremanezumab for the Treatment of Cluster Headache Study Group. Fremanezumab for the preventive treatment of chronic cluster headache. *N Engl J Med*. 2021;384(19):1808-1819.</li>
                <li>Goadsby PJ, Bigal ME, Yeung PP, et al. Efficacy and safety of galcanezumab in patients with episodic cluster headache: results from a phase 3, double-blind, randomized, placebo-controlled study. *Lancet Neurol*. 2019;18(11):980-988.</li>
                <li>Ailani J, Farmer K, and the American Headache Society. Migraine in Pregnancy. *Headache*. 2021;61(10):1448-1457.</li>
                <li>O'Brien HL, Hershey AD. Migraine in children and adolescents. *Curr Pain Headache Rep*. 2021;25(4):27.</li>
                <li>Dodick DW, Ashina M, Bendtsen L, et al. ARISE: A Phase 3 Randomized Trial of Erenumab for Episodic Migraine. *JAMA Neurol*. 2018;75(4):465-473.</li>
                <li>Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. *N Engl J Med*. 2017;377(22):2113-2122.</li>
                <li>Dodick DW, Silberstein SD, Bigal ME, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. *JAMA*. 2018;319(19):1999-2008.</li>
                <li>Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the episodic cluster headache prevention. *Headache*. 2021;61(4):618-629.</li>
                <li>Lipton RB, Goadsby PJ, Smith J, et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). *Neurology*. 2020;95(16):e2101-e2112.</li>
                <li>Ashina M, Saper J, Tepper SJ, et al. Eptinezumab in patients with chronic migraine: a randomized, double-blind, placebo-controlled phase 3 trial (PROMISE-2). *Lancet Neurol*. 2020;19(7):591-600.</li>
                <li>Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the Acute Treatment of Migraine: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study. *Neurology*. 2019;93(12):e1296-e1307.</li>
                <li>Goadsby PJ, Croop R, Ayata C, et al. Efficacy and safety of rimegepant oral dissolving tablet for the acute treatment of migraine: A Phase 3, randomized, controlled trial. *The Lancet*. 2019;394(10200):737-745.</li>
                <li>Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, double-blind, randomized, placebo-controlled trial. *Lancet*. 2021;397(10268):51-60.</li>
                <li>Croop R, Madonia J, Stock D, et al. Zavegepant Nasal Spray for the Acute Treatment of Migraine: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. *Neurology*. 2023;100(24):e2440-e2452.</li>
                <li>Goadsby PJ, Grosberg BM, Mauskop A, et al. Effect of noninvasive vagus nerve stimulation on acute migraine treatment: an open-label pilot study. *Cephalalgia*. 2014;34(12):986-993.</li>
                <li>Diener HC, Limmroth V. Medication-overuse headache: a review of current concepts. *Cephalalgia*. 2004;24(2):98-106.</li>
            </ul>
        </section>

    </main>

    <script>
        function toggleAccordion(element) {
            const content = element.nextElementSibling;
            const svg = element.querySelector('svg');
            content.classList.toggle('open');
            svg.classList.toggle('rotate-180');
        }
        // Initialize SVG rotation for already open accordions if any (not applicable here as all start closed)
        document.querySelectorAll('.accordion-header').forEach(header => {
            const svg = header.querySelector('svg');
            if (header.nextElementSibling.classList.contains('open')) {
                svg.classList.add('rotate-180');
            }
        });
    </script>
</body>
</html>
